GlassScriptPhysician profile
Candice A Hammerton
NPI 1558306910
$4,185.80
in general payments reported to CMS, 2019-2025
36 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $437 · 2023: $1,152 · 2024: $862 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,000.96 |
| Education | $356.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $528.67 | 2021-2024 | Xtandi |
| Janssen Biotech, INC. | $471.56 | 2023-2025 | Erleada |
| Sumitomo Pharma America, INC. | $436.77 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $354.82 | 2022-2025 | Lynparza |
| Abbvie INC. | $223.85 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.54 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $183.40 | 2022-2025 | Bridion, Lynparza, Keytruda |
| Urogen Pharma, INC. | $181.79 | 2025 | |
| Tolmar, INC. | $160.35 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $159.39 | 2024-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $107.25 | 2021-2022 | |
| Olympus America INC. | $105.75 | 2025 | Itind System |
| 180 Medical, INC. | $102.67 | 2022-2024 | Cure Ultra Catheter, Gentlecath |
| Teleflex LLC | $91.69 | 2023-2025 | Barrigel, Urolift |
| Pfizer INC. | $83.18 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $78.37 | 2021-2024 | |
| Progenics Pharmaceuticals, INC. | $77.92 | 2023-2025 | Pylarify |
| Procept Biorobotics Corporation | $65.00 | 2023 | Aquabeam Robotic System |
| Myriad Genetic Laboratories, INC. | $63.28 | 2023-2025 | Prolaris, Myrisk |
| Intuitive Surgical, INC. | $62.74 | 2023 | Da Vinci Surgical System |
| Dentsply Ih Ab | $52.78 | 2024 | Lofric |
| Amgen INC. | $46.09 | 2021 | |
| Convatec INC. | $39.54 | 2024 | |
| Axonics, INC. | $36.44 | 2023-2024 | Axonics |
| Myovant Sciences INC. | $36.05 | 2021-2022 | |
| Halozyme INC | $27.76 | 2023 | |
| Allergan, INC. | $24.00 | 2022 | |
| Boston Scientific Corporation | $21.21 | 2025 | Bulkamid |
| Urovant Sciences INC | $21.07 | 2022 | |
| Dentsply Ih INC. | $20.48 | 2022 | |
| Genzyme Corporation | $19.71 | 2022 | |
| Foundation Medicine, INC. | $19.03 | 2023 | Foundationone Liquid Cdx |
| Antares Pharma, INC. | $18.06 | 2023 | Nocdurna, Tlando, Xyosted |
| Rochester Medical Corporation | $14.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.64 | 2025 | |
| Calyxo, INC. | $13.15 | 2024 | Cvac Aspiration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Hammerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.